ClinicalTrials.gg
Drug

Regorafenib clinical trials

Also written Stivarga and BAY 73-4506.

studies test it
173
open now
27
in phase 3
17
first study started
2007

How each study uses regorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the regorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Sept 2012 · STIVARGA · NDA 203085 (FDA, Drugs@FDA)
European Union
26 Aug 2013 · Stivarga · EMEA/H/C/002573 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Regorafenib
108
Regorafenib (Stivarga, BAY73-4506)
19
Regorafenib (BAY73-4506)
5
Regorafenib (BAY 73-4506)
4
multikinase inhibitor BAY 73-4506
3

Brand

Stivarga
62

Development codes

BAY 73-4506
27

Studies by the year they started

173 studies that test it; most in 2014 (22)

Studies that test regorafenib, by start year
YearStudies
20071
20081
20094
20104
20116
20121
201315
201422
201518
201616
20174
20189
201912
202010
202112
202210
20239
20247
20256
20266

By phase

A phase 1/2 study counts in both.

Phase 1
48
Phase 2
122
Phase 3
17
Phase 4
3
No phase
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 40 · Other 133

Bayer (32) · Asan Medical Center (5) · Academic and Community Cancer Research United (4) · Memorial Sloan Kettering Cancer Center (4) · Centre Hospitalier Universitaire de Besancon (3) · Australasian Gastro-Intestinal Trials Group (3) · Istituto Oncologico Veneto IRCCS (3) · UNICANCER (3)

Often tested with

Tested in the same studies.

Nivolumab (15) · Durvalumab (4) · Irinotecan (4) · Trametinib (4) · Pembrolizumab (4) · Cabozantinib (4) · Capecitabine (3) · Cetuximab (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Regorafenib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 10

Studies that test regorafenib.

Studies

Open first, then newest update. How each study uses regorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 173

See all 173 studies that test regorafenib →

Given beside what is tested · 66 — regorafenib is usual care or a partner of the new treatment

Showing 20 of 66.

As the comparator · 24 — what is tested is compared with regorafenib

Showing 20 of 24.

Codes

What other systems call regorafenib · ClinicalTrials.gg INT005858

  • MeSH (NLM) C559147regorafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) MGN125FS9DREGORAFENIBConfirmed FDA, Wikidata
  • RxNorm 1371319Confirmed FDA, Wikidata
  • Wikidata Q27137075regorafenib monohydrateConfirmed FDA, Wikidata
  • NCI Thesaurus C184955RegorafenibOne source FDA

Also registered as regorafenib anhydrous (UNII 24T2A1DOYB · RxNorm 1312397).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.